Highlights Chugai Pharmaceutical Co., Ltd.

Stocks

4519

JP3519400000

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 07:30:00 10/07/2026 BST			5-day change	1st Jan Change
7,389.00 ^JPY	+0.41%		-3.31%	-10.36%

06-15	Goldman Sachs Upgrades Chugai Pharmaceutical to Buy from Neutral; Price Target is 8,950 Yen	MT
05-26	Major Asian Stock Markets Fall Amid Renewed Middle East Tensions	MT

Highlights

04-27	Keyence, Fanuc Shares Climb, Chugai Declines as Japan Stocks Mixed After Earnings	MT
04-24	Chugai Pharmaceutical's Q1 Income Rises 19%	MT
04-24	Chugai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-23	Chugai Pharmaceutical Co., Ltd. Announces Discontinuation Of Development Of GYM329 In Spinal Muscular Atrophy And Facioscapulohumeral Muscular Dystrophy	CI
01-29	Chugai Pharmaceutical's Profit Climbs 12% in 2025	MT
01-29	Chugai Pharmaceutical Co., Ltd. Proposes Year-End Dividend for the Fiscal Year Ended December 31, 2025, Effective March 27, 2026	CI
01-29	Chugai Pharmaceutical Co., Ltd. Proposes Special Dividend for the Fiscal Year Ended December 31, 2025, Effective March 27, 2026	CI
01-29	Chugai Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year End Fiscal Year Ending December 31, 2026	CI
01-29	Chugai Pharmaceutical Co., Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
12-30	Chugai Completes Merger With Renalys Pharma	MT
12-29	Chugai Pharmaceutical Co., Ltd. completed the acquisition of Renalys Pharma.	CI
11-18	Chugai Pharmaceutical to Absorb Renalys Pharma Following Full Acquisition	MT
24/10/25	Chugai Pharmaceutical to Acquire Renalys Pharma to Strengthen Kidney Disease Drug Portfolio	MT
24/10/25	Chugai Pharmaceutical's Net Income Rises 3.3% in Nine Months Period	MT
24/10/25	Renalys Pharma to be acquired by Chugai Pharmaceutical	RE
24/10/25	Chugai Pharmaceutical Co Ltd - Notice concerning making Renalys Pharma, Inc. a wholly-owned subsidiary	RE
23/10/25	Chugai Pharmaceutical Co., Ltd. agreed to acquire Renalys Pharma for ¥31 billion.	CI
17/09/25	Chugai Pharmaceutical Co., Ltd. Announces Positive Topline Results from ACHIEVE-3	CI
27/08/25	Chugai Pharmaceutical Co., Ltd. Announces Positive Topline Results from the Phase 3 Attain-2 Trial, Evaluating Orforglipron	CI
08/08/25	Chugai Pharmaceutical Co., Ltd. Announces Positive Topline Phase 3 Results from Attain-1	CI
24/07/25	Chugai Pharmaceutical to Invest 80 Billion Yen to Build Eco-Friendly Lab in Tokyo	MT
24/07/25	Chugai Pharmaceutical Profit Up 4.4% in H1	MT
24/07/25	Chugai Pharmaceutical Co., Ltd. to Construct a New Laboratory Building ' UKX' to Strengthen Manufacturing Process Development Capabilities and Advance Environmental Initiatives Towards Top I 2030	CI
07/07/25	Chugai Pharmaceutical Co., Ltd. and Gero Pte. Ltd. Enter into Joint Research and License Agreement to Develop Novel Therapies for Age-Related Diseases	CI
25/04/25	Chugai Pharmaceutical's Net Income Jumps 31% in Three Months Ended March 31	MT